US Patent

US8598185 — Unitary pharmaceutical dosage form

Formulation · Assigned to Bristol Myers Squibb and Gilead Sciences LLC · Expires 2029-04-28 · 3y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a unitary oral dosage form containing efavirenz, emtricitabine, and tenofovir DF in a stabilizing configuration.

USPTO Abstract

In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.

Drugs covered by this patent

Patent Metadata

Patent number
US8598185
Jurisdiction
US
Classification
Formulation
Expires
2029-04-28
Drug substance claim
No
Drug product claim
Yes
Assignee
Bristol Myers Squibb and Gilead Sciences LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.